ICON Public stock

ICLR · NASDAQ · USD

Compare ICON Public
$190.06Change from previous close: −2.36%Absolute change: −$4.59

Close · November 16, 2026

Price history

+21.45% over the period

1 year: from $156.49 (November 17, 2025) to $190.06 (November 16, 2026), +21.45%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 16, 2026$190.06
October 30, 2026$211.36
September 30, 2026$169.99
August 31, 2026$164.99
July 31, 2026$163.57
June 30, 2026$173.71
May 29, 2026$136.07
April 30, 2026$118.33
March 31, 2026$110.66
February 27, 2026$108.14
January 30, 2026$180.25
December 31, 2025$182.22
November 28, 2025$185.00
November 17, 2025$156.49

At a glance

  • The company

    Provides outsourced clinical research and development services for pharmaceutical, biotechnology and medical device companies worldwide

  • Latest results

    Quarter to September 30, 2026 · EPS $2.66 (estimate $2.64)

TickerLandia's take on ICON Public

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$66.57
52-wk high$219.04

−13.23% from the 52-week high

Analysts · 18 analysts

Average target$231.29+21.70% vs. price

Buy 10 · Hold 8 · Sell 0 · Buy

TickerLandia Fingerprint: ICON Public

Compared with similar companies: very strong momentum, very low profitability, and very high risk.

Financials and price compared with 27 companies in the diagnostics & research industry, worldwide. Momentum and risk compared with 883 North American stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

ICON Public is pricier than in the past and pricier than similar companies

On the latest fiscal year's earnings (2025), ICON Public's P/E today is 65.5, above the median of its last 10 fiscal years (28.5; between 16.2 and 137.6 from 2016 to 2025). ICON Public's P/E (trailing 12 months): 77.9, +106% against the median of a group of 9 similar companies (37.7).

P/E compared with its history

Compared with 9 similar companies

ICON Public's metrics compared with similar companies
MetricICON PublicPosition in the groupBand
P/E (trailing 12 months)77.9High
Forward P/E16.8Low
Operating margin2.7%Low
ROE4.7%Middle
Debt/equity0.38Middle

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: ICON Public. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$2.02B

Latest quarter · Q3 2026

Net income

$122.13M

Latest quarter · Q3 2026

Quarterly net margin

6.0%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
$14.58B
P/E
77.9
EPS
$2.50
Volume
966.54K
Daily trading
€228.59M
Dividend yield
0.00%

How ICON Public is changing

All results
  • Revenue grew 24.2% a year on average over the last 5 years

  • Operating margin fell from 10.3% to 5.4%

  • Shares outstanding up 48.2% in 5 years

Returns

ICON Public returns

$1,000 invested in ICON Public 5 years ago, on November 16, 2021, would be worth $666 today: −33.45% in total, −7.82% per year. This is the price return only: dividends are excluded.

PeriodICON PublicS&P 500$1,000 becomes
1 month+11.68%−3.12%$1,117
6 months+63.31%+2.07%$1,633
Year to date+4.30%+10.46%$1,043
1 year+21.45%+13.33%$1,215
3 years−29.36%+67.73%$706
5 years−33.45%+60.86%$666
10 years+146.64%+247.35%$2,466

Over the last 6 months it has done better than 93% of the stocks in the Healthcare sector.

Price only, without dividends. Calculate your investment

The chart in detail

ICON Public: technical analysis

ICON Public is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 45.1% below its all-time closing high ($346.20, July 16, 2024).

Trend
Upward
RSI (14 sessions)
48
Between 30 and 70
vs 200-session average
+29.52%

Support and resistance

Price areas where ICON Public has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance$191.33+0.67%3 touches, last on January 27, 2026
  2. Last price$190.06
  3. Support$179.47−5.57%4 touches, last on October 6, 2026
  4. Support$172.65−9.16%3 touches, last on January 20, 2026
  5. Support$162.32−14.59%2 touches, last on September 18, 2026

Volatility and risk

Over the last year it has moved more than the S&P 500.

Beta (1 year) vs S&P 500
1.26
Volatility (60 sessions, annualised)
49.7%
Largest fall in the last year
−60.54%

In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

ICON Public: seasonality

Average monthly price change over 29 years

+1.7%Jan+0.8%Feb−1.8%Mar+0.8%Apr+2.1%May+8.1%Jun+6.4%Jul−1.6%Aug+0.8%Sep−2.2%Oct+1.5%Nov+3.1%Dec

Over the last 29 years, the strongest month for ICON Public has been June: +8.11% on average, positive in 22 years out of 29. The weakest has been October: −2.24% on average, positive in 13 years out of 29. November, the current month, has been positive in 17 years out of 28 (+1.49% on average).

Show chart data
MonthAverageMedianPositive years
January+1.72%+1.51%16 of 28
February+0.85%+1.02%15 of 28
March−1.82%+2.02%17 of 28
April+0.83%+0.02%14 of 28
May+2.14%+3.92%17 of 28
June+8.11%+4.94%22 of 29
July+6.36%+9.02%24 of 29
August−1.62%−1.94%12 of 29
September+0.84%+1.41%17 of 29
October−2.24%−0.93%13 of 29
November+1.49%+2.39%17 of 28
December+3.12%+2.22%18 of 28

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

ICON Public and its competitors

With 40,250 employees, ICON Public Limited Company provides outsourced development and commercialization services to pharmaceutical, biotechnology and medical device companies, as well as to government and public health organizations. Its work covers the clinical development process from compound selection through Phase I-IV studies, including trial management, data solutions, contract staffing and decentralized or hybrid trials. Its testing offering includes bioanalytical, biomarker, vaccine and central laboratory services, and its therapeutic areas include oncology, cardiovascular, central nervous system and infectious diseases.

Headquarters
Dublin, Ireland
Employees
40,250
Founded
1990
Chief executive
Barry Balfe
ICON Public and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
ICON PublicICLR$14.58B2.7%77.9+63.31%
Charles River Laboratories InternationalCRL$16.19B14.3%367.4+123.10%
RevvityRVTY$17.84B16.3%70.5+59.49%
Medpace HoldingsMEDP$19.12B21.4%38.0+57.36%
Guardant HealthGH$20.52B-39.4%—+52.78%
Quest DiagnosticsDGX$28.56B14.9%25.9+40.23%

Same industry or related industries, similar size. Compare ICON Public with its competitors · Full profile